PMID- 19307991
OWN - NLM
STAT- MEDLINE
DCOM- 20090515
LR  - 20171116
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Linking)
VI  - 32
IP  - 1
DP  - 2009 Jan
TI  - CD40-activated apoptotic tumor cell-pulsed dendritic cell could potentially 
      elicit antitumor immune response: involvement of up-regulation of B7-H3 
      expression.
PG  - 29-35
LID - 10.1097/CJI.0b013e31818c8816 [doi]
AB  - Dendritic cells (DCs) initiate and direct immune responses. Previous in vitro and 
      in vivo studies have showed that DCs matured with CD40 linking signal could 
      potentially elicit and boost antitumor immunity, however, its molecular mechanism 
      remain elusive. This study demonstrates that expression of B7-H3 on apoptotic 
      cell-loading DCs is up-regulated markedly by CD40 activation but not by tumor 
      necrosis factor-alpha stimulation. There was no significant difference found with 
      CD40, CD80, or CD86 expressions when activated by CD40 or tumor necrosis 
      factor-alpha stimulation. In tumor-bearing mice, T cells conditioned with 
      B7-H3-blocked on CD40-activated apoptotic tumor cell-pulsed DCs had a decreased 
      ability to inhibit tumor growth. Therefore, it is hypothesized that high levels 
      of B7-H3 expression contributes to the ability of CD40-activated tumor associated 
      DCs in eliciting efficient antitumor immune response, given this fact the 
      potentially significant clinical implications, CD40-activated DCs merit further 
      considerations when preparing DCs for clinical application.
FAU - Chen, Cheng
AU  - Chen C
AD  - Clinical Immunology Laboratory of Jiangsu Province, The First Affiliated Hospital 
      of Soochow University, Suzhou, China.
FAU - Zhu, Yi-Bei
AU  - Zhu YB
FAU - Qu, Qiu-Xia
AU  - Qu QX
FAU - Ge, Yan
AU  - Ge Y
FAU - Huang, Jian-An
AU  - Huang JA
FAU - Wang, Yong
AU  - Wang Y
FAU - Zhang, Xue-Guang
AU  - Zhang XG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7 Antigens)
RN  - 0 (B7-1 Antigen)
RN  - 0 (CD40 Antigens)
RN  - 0 (Cd276 protein, mouse)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Apoptosis/drug effects
MH  - B7 Antigens
MH  - B7-1 Antigen/immunology/metabolism
MH  - CD40 Antigens/immunology/*metabolism
MH  - Cell Line, Tumor
MH  - Cisplatin/pharmacology
MH  - Dendritic Cells/*immunology/metabolism
MH  - Female
MH  - Lymphoma, B-Cell/*immunology/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - T-Lymphocytes/*immunology/metabolism
MH  - Tumor Necrosis Factor-alpha/immunology/*metabolism
EDAT- 2009/03/25 09:00
MHDA- 2009/05/16 09:00
CRDT- 2009/03/25 09:00
PHST- 2009/03/25 09:00 [entrez]
PHST- 2009/03/25 09:00 [pubmed]
PHST- 2009/05/16 09:00 [medline]
AID - 00002371-200901000-00004 [pii]
AID - 10.1097/CJI.0b013e31818c8816 [doi]
PST - ppublish
SO  - J Immunother. 2009 Jan;32(1):29-35. doi: 10.1097/CJI.0b013e31818c8816.